治疗性核酸适体的研究进展  

Proceedings of therapeutic aptamers

作　　者：王玥莹[1] 李晓玲[1] 宋溦[1] 喻云梅 赵祖国[1] 刘仿[1] 

机构地区：[1]广东医学院微生物与免疫学教研室,湛江524023 [2]解放军第422医院,湛江524023

出　　处：《中国新药杂志》2014年第6期660-664,共5页Chinese Journal of New Drugs

基　　金：国家自然科学基金(81301473/H1911;81273078/H2604);湛江市科技计划项目(2012C3101045);东莞市科技计划项目(201110515200001);解放军第422医院医学科研项目(201216215)

摘　　要：核酸适体是采用指数富集配体的系统进化技术(systematic evolution of ligands by exponential enrichment,SELEX)从随机单链核苷酸库中筛选出的能与不同靶分子高特异性、高亲和力结合的单链DNA或RNA。核酸适体结合靶标的方式与抗原-抗体间的作用机制相似,且其特性很多方面可与抗体相媲美。核酸适体作为一种新型的生物药物越来越受到重视。本文主要介绍核酸适体在肿瘤、感染性疾病和自身免疫性疾病等疾病治疗中的研究进展。Nucleic acid aptamers refer to single-stranded DNA or RNA selected from random single nucleo- tide ever library by the technique of SELEX （Exponential Enrichment ligand system evolution）. Nucleic acid aptamers can bind to different target molecules with high specificity and affinity. The mechanism of aptamer binding its target is similar to the interaction of antibody with antigen. Advantages of aptamers make them a rival to antibod- ies. As new biological drugs, aptamers are drawing more and more attention. This paper mainly focuses on the re- search progress of nucleic acid aptamers on cancer, infectious diseases, autoimmune diseases and other ailments.

关 键 词：核酸适体 药物 肿瘤 感染性疾病 自身免疫性疾病 

分 类 号：R979.5[医药卫生—药品]